Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nacresertib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nacresertib (ABBV-105) is an orally bioavailable small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is a critical signaling node downstream of Toll-like receptors (TLRs) and Interleukin-1 receptors (IL-1Rs), which are essential components of the innate immune system and drivers of pro-inflammatory cytokine production. By selectively inhibiting IRAK4, nacresertib aims to modulate the inflammatory response in various autoimmune and inflammatory conditions. Developed by AbbVie, nacresertib has been investigated both as a monotherapy and in combination with the JAK inhibitor upadacitinib (the combination is designated as ABBV-599). Clinical development has targeted diseases such as rheumatoid arthritis, atopic dermatitis, and systemic lupus erythematosus, reaching Phase 2 in global clinical trials.
- Other names
- nascertib
02
Targets
BTK (Bruton tyrosine kinase)IRAK4 (Interleukin-1 receptor associated kinase 4)
Beyond the preview
Go deeper on nacresertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nacresertib.